Clinical Trial Update: A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) [Phase 2]

View source ↗

Summary

Phase 2 study compares subcutaneous pembrolizumab coformulated with hyaluronidase alfa (MK-3475A) to intravenous pembrolizumab in multiple tumor types; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Pembrolizumab coformulated with hyaluronidase alfa (MK-3475A) (pembrolizumab; hyaluronidase alfa)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-08